Linked e-resources
Details
Table of Contents
Author Biographies; Chapter 1: Introduction toßInsulin Therapies; 1.1 Introduction; 1.2 Classification; 1.3 The Global Burden ofßDiabetes; 1.4 The Human Insulin Molecule; 1.4.1 Effect ofßInsulin onßMetabolism; 1.5 History ofßInsulin Therapy; 1.5.1 The New Era ofßInsulin Therapies; 1.5.2 Insulin Management: Combining Art withßScience; 1.6 Summary; References; Further Reading; Chapter 2: Existing Insulin Therapies; 2.1 Introduction; 2.2 Animal Insulin; 2.3 Human Recombinant Insulin; 2.3.1 U-500 Insulin; 2.3.2 Animal Versus Human Insulin; 2.4 Insulin Analogs; 2.4.1 Rapid-Acting Analogs.
2.4.2 Long-Acting Insulin Analogs2.4.2.1 Glargine; 2.4.2.2 Detemir; 2.4.2.3 Long-Acting Basal Analog: Insulin Degludec; 2.4.2.4 Insulin Degludec 200; 2.4.2.5 Summary; 2.4.3 Premixed Insulin; 2.4.3.1 IDegAsp; 2.5 Summary; References; Chapter 3: Emerging Insulin Therapies; 3.1 Injectable Insulin Products; 3.1.1 Ultra-Rapid-Acting Insulin; 3.1.2 Long-Acting Basal Insulin Peglispro; 3.1.3 Glargine U300 Insulin; 3.1.4 Fixed Ratio Combinations; 3.1.4.1 IDegLira; 3.1.4.2 LixiLan; 3.2 Non-injectable Insulin Products; 3.2.1 Inhaled Insulin; 3.2.2 Oral Insulin; 3.2.3 Buccal Insulin.
3.3 Biosimilar Insulin3.4 Summary; References; Further Reading; Chapter 4: Insulin Management inßTypeß2 Diabetes; 4.1 Introduction; 4.2 Insulin Therapy inßType 2 Diabetes; 4.2.1 Factors Impacting onßInsulin Initiation andßClinical Inertia; 4.2.2 Patient Education; 4.2.3 Early Use ofßInsulin inßType 2 Diabetes; 4.3 Insulin Regimens; 4.3.1 Basal Insulin Regimen; 4.3.2 Combination Therapy withßConventional Oral Glucose-Lowering Agents; 4.3.3 Combination Therapy withßNewer Classes ofßGlucose-Lowering Agents; 4.3.3.1 Insulin inßCombination withßGLP-1RAs.
4.3.3.2 Insulin inßCombination withßDPP-4 Inhibitors4.3.3.3 Insulin inßCombination withßSGLT2 Inhibitors; 4.3.4 Basal-Plus Insulin Regimen; 4.3.5 Twice-Daily Premixed Insulin Regimen; 4.3.6 Prandial-Only Insulin Regimen; 4.3.7 Basal-Bolus Insulin Regimen; 4.4 Intensifying Insulin Therapy withßInadequately Controlled Type 2 Diabetes; 4.5 Summary; References; Further Reading; Chapter 5: Insulin Management inßTypeß1 Diabetes; 5.1 Overview; 5.2 The Benefits ofßTight Glycemic Control inßType 1 Diabetes; 5.2.1 Adherence toßInsulin Therapy inßIndividuals withßT1DM.
5.2.2 Role ofßContinuous Glucose Monitoring forßIntensive Insulin Therapy5.2.3 Sensor-Augmented Insulin Pump Therapy; 5.3 Insulin Regimens inßType 1 Diabetes; 5.3.1 Conventional Insulin Regimen; 5.3.1.1 Efficacy andßReal-Life Experience withßConventional Insulin Regimen; 5.3.1.2 Indications toßChange or Intensify Insulin Therapy fromßaßConventional Insulin Regimen; 5.3.2 Multiple-Daily Injections or Basal-Bolus Insulin Regimen; 5.3.2.1 Indications toßChange or Intensify Insulin Therapy fromßanßMDI Regimen; 5.4 Continuous Subcutaneous Insulin Infusion or Insulin Pump Therapy.
2.4.2 Long-Acting Insulin Analogs2.4.2.1 Glargine; 2.4.2.2 Detemir; 2.4.2.3 Long-Acting Basal Analog: Insulin Degludec; 2.4.2.4 Insulin Degludec 200; 2.4.2.5 Summary; 2.4.3 Premixed Insulin; 2.4.3.1 IDegAsp; 2.5 Summary; References; Chapter 3: Emerging Insulin Therapies; 3.1 Injectable Insulin Products; 3.1.1 Ultra-Rapid-Acting Insulin; 3.1.2 Long-Acting Basal Insulin Peglispro; 3.1.3 Glargine U300 Insulin; 3.1.4 Fixed Ratio Combinations; 3.1.4.1 IDegLira; 3.1.4.2 LixiLan; 3.2 Non-injectable Insulin Products; 3.2.1 Inhaled Insulin; 3.2.2 Oral Insulin; 3.2.3 Buccal Insulin.
3.3 Biosimilar Insulin3.4 Summary; References; Further Reading; Chapter 4: Insulin Management inßTypeß2 Diabetes; 4.1 Introduction; 4.2 Insulin Therapy inßType 2 Diabetes; 4.2.1 Factors Impacting onßInsulin Initiation andßClinical Inertia; 4.2.2 Patient Education; 4.2.3 Early Use ofßInsulin inßType 2 Diabetes; 4.3 Insulin Regimens; 4.3.1 Basal Insulin Regimen; 4.3.2 Combination Therapy withßConventional Oral Glucose-Lowering Agents; 4.3.3 Combination Therapy withßNewer Classes ofßGlucose-Lowering Agents; 4.3.3.1 Insulin inßCombination withßGLP-1RAs.
4.3.3.2 Insulin inßCombination withßDPP-4 Inhibitors4.3.3.3 Insulin inßCombination withßSGLT2 Inhibitors; 4.3.4 Basal-Plus Insulin Regimen; 4.3.5 Twice-Daily Premixed Insulin Regimen; 4.3.6 Prandial-Only Insulin Regimen; 4.3.7 Basal-Bolus Insulin Regimen; 4.4 Intensifying Insulin Therapy withßInadequately Controlled Type 2 Diabetes; 4.5 Summary; References; Further Reading; Chapter 5: Insulin Management inßTypeß1 Diabetes; 5.1 Overview; 5.2 The Benefits ofßTight Glycemic Control inßType 1 Diabetes; 5.2.1 Adherence toßInsulin Therapy inßIndividuals withßT1DM.
5.2.2 Role ofßContinuous Glucose Monitoring forßIntensive Insulin Therapy5.2.3 Sensor-Augmented Insulin Pump Therapy; 5.3 Insulin Regimens inßType 1 Diabetes; 5.3.1 Conventional Insulin Regimen; 5.3.1.1 Efficacy andßReal-Life Experience withßConventional Insulin Regimen; 5.3.1.2 Indications toßChange or Intensify Insulin Therapy fromßaßConventional Insulin Regimen; 5.3.2 Multiple-Daily Injections or Basal-Bolus Insulin Regimen; 5.3.2.1 Indications toßChange or Intensify Insulin Therapy fromßanßMDI Regimen; 5.4 Continuous Subcutaneous Insulin Infusion or Insulin Pump Therapy.